人福医药子公司撤回重组质粒-肝细胞生长因子注射液的注册申请

Core Viewpoint - The company announced that its subsidiary, Wuhan Guanggu Renfu Biopharmaceutical Co., Ltd., has received a notice from the National Medical Products Administration regarding the termination of its drug registration application for the recombinant plasmid-hepatocyte growth factor injection [1] Group 1 - The company holds an 81.30% stake in Wuhan Guanggu Renfu [1] - The withdrawal of the drug registration application will allow Guanggu Renfu to improve research data and reapply for drug registration [1] - The company expects that this matter will not have a significant impact on its current performance [1]